2025 Q4 -tulosraportti
Vain PDF
39 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 953 | - | - | ||
| 7 618 | - | - | ||
| 784 | - | - | ||
| 357 | - | - | ||
| 33 323 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·7 min sittenTHEY ARE NOT SELLING A DRUG. THEY ARE SELLING THE KEY. 🧬🔑 There is a fundamental difference. A pharmaceutical company develops one treatment for one disease. One approval. One market. Circio does something else. They develop the technology that makes others' treatments better. AAV gene therapy has a dosing problem. circVec solves it. mRNA-based CAR-T lasts a few days. circVec lasts months. Liver expression is a toxicity problem. circVec reduces it. It is not one treatment. It is one key. And keys can be licensed to everyone who needs to unlock the same problem. Heart. Eye. CNS. CAR-T. Autoimmune diseases. Cancer. Vaccines. Each field is a new market. Each partner pays for access. It is not a product case. It is an infrastructure case. And infrastructure is not priced as one program. It is priced as control over an entire field. We know what we own. ♟️🧱🍷- ·16 min sittenERIK SPEAKS THURSDAY 28. MAY. AT 10:00. 🧬🎤 This coming Thursday at 10:00, Erik Wiklund will hold a live webcast. He will summarize what actually happened in Boston at ASGCT. No dry press release. No interpretation of stock exchange announcements. Erik himself. Live. In Norwegian. You can submit questions in advance directly to erik.wiklund@circio.com. It is not often that a CEO in biotech sits down and explains the data face-to-face directly to the shareholders. Seize the opportunity. Submit questions about the in vivo program and the way forward. We know what we own. ♟️🧱🍷
·9 min sittenBennyz, you know you think long-term, but what do you think about the next weeks with warrants? Do you think the stock will rise a bit so that people will buy their warrants? 
·28 min sittenCircio, as is known, entered into an evaluation agreement in April with Acuitas Therapeutics to develop a new type of in vivo CAR-T cell therapy. News article at NRK today about what chief physician Fredrik Schjesvold says "is the best cancer treatment we have today". Too expensive - says the decision-making forum. News article within the professional field, for information for those who are interested. https://www.nrk.no/rogaland/beslutningsforum-seier-nei-for-andre-gong-til-_den-beste-kreftbehandlinga_-mot-beinmergskreft-1.17823907- ·46 min sitten"Tekinvestor "Some thoughts and Ref. Lilly's Acquisition of Engage now - The most interesting thing is actually not BP's individual deals, but the pattern we can see emerging… Big Pharma no longer just buys finished medicines – they buy platforms that can potentially broadly improve genetic medicine - Delivery, expression, RNA technology, in vivo cell therapy etc. Engage Bio was thus now acquired by EL without published clinical data (as far as I can see) That says something about how much value BP now attributes to enablement technology and platform At the same time, Circio has shown very strong preclinical data received an oral presentation at ASGCT and gone from feasibility to in vivo with a BP partner. And more … Then the question is: What could circVec be worth if the technology actually proves to work broadly within AAV, LNP, and other in vivo solutions? To me, this looks more and more like a race for platforms and infrastructure layers – and not just individual products. If Circio gets an upfront deal or stronger BP validation, which I believe is entirely possible within the year, I'm not sure that an early acquisition is necessarily the most interesting outcome… And several major shareholders agree here! Because if our technology / platform actually gets validated more broadly, then it's hard to imagine anything other than the market's understanding of the case changing significantly! Yes - This is still risk biotech and some elements remain to be proven… ,but my assessment is that the risk/reward is very interesting here, precisely because the market still largely prices Circio essentially as a small Norwegian preclinical biotech company — while signals from the sector and BP point towards something potentially much larger! What happens if we actually get the validation they are working towards? I am a proponent of being able to think big! But even I can't quite imagine how big this could become!!?"
·5 t sittenhttps://strawpoll.com/7MZ0kLv7pgo Big Pharma who? Who do you think is testing circVec in CNS behind the scenes? (Feasibility study since November 2025) Vote who you BELIEVE, and not who you hope. As most know, it's a top 5 largest Big Pharma. I have added more than 5, as it's hard to assess who is actually bigger than whom. 💰
·24 min sittenNovo. They have shut down their production on Funen. Brilliant if they could use the new factory for Circio 😁😁
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
39 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·7 min sittenTHEY ARE NOT SELLING A DRUG. THEY ARE SELLING THE KEY. 🧬🔑 There is a fundamental difference. A pharmaceutical company develops one treatment for one disease. One approval. One market. Circio does something else. They develop the technology that makes others' treatments better. AAV gene therapy has a dosing problem. circVec solves it. mRNA-based CAR-T lasts a few days. circVec lasts months. Liver expression is a toxicity problem. circVec reduces it. It is not one treatment. It is one key. And keys can be licensed to everyone who needs to unlock the same problem. Heart. Eye. CNS. CAR-T. Autoimmune diseases. Cancer. Vaccines. Each field is a new market. Each partner pays for access. It is not a product case. It is an infrastructure case. And infrastructure is not priced as one program. It is priced as control over an entire field. We know what we own. ♟️🧱🍷
- ·16 min sittenERIK SPEAKS THURSDAY 28. MAY. AT 10:00. 🧬🎤 This coming Thursday at 10:00, Erik Wiklund will hold a live webcast. He will summarize what actually happened in Boston at ASGCT. No dry press release. No interpretation of stock exchange announcements. Erik himself. Live. In Norwegian. You can submit questions in advance directly to erik.wiklund@circio.com. It is not often that a CEO in biotech sits down and explains the data face-to-face directly to the shareholders. Seize the opportunity. Submit questions about the in vivo program and the way forward. We know what we own. ♟️🧱🍷·9 min sittenBennyz, you know you think long-term, but what do you think about the next weeks with warrants? Do you think the stock will rise a bit so that people will buy their warrants?
- ·28 min sittenCircio, as is known, entered into an evaluation agreement in April with Acuitas Therapeutics to develop a new type of in vivo CAR-T cell therapy. News article at NRK today about what chief physician Fredrik Schjesvold says "is the best cancer treatment we have today". Too expensive - says the decision-making forum. News article within the professional field, for information for those who are interested. https://www.nrk.no/rogaland/beslutningsforum-seier-nei-for-andre-gong-til-_den-beste-kreftbehandlinga_-mot-beinmergskreft-1.17823907
- ·46 min sitten"Tekinvestor "Some thoughts and Ref. Lilly's Acquisition of Engage now - The most interesting thing is actually not BP's individual deals, but the pattern we can see emerging… Big Pharma no longer just buys finished medicines – they buy platforms that can potentially broadly improve genetic medicine - Delivery, expression, RNA technology, in vivo cell therapy etc. Engage Bio was thus now acquired by EL without published clinical data (as far as I can see) That says something about how much value BP now attributes to enablement technology and platform At the same time, Circio has shown very strong preclinical data received an oral presentation at ASGCT and gone from feasibility to in vivo with a BP partner. And more … Then the question is: What could circVec be worth if the technology actually proves to work broadly within AAV, LNP, and other in vivo solutions? To me, this looks more and more like a race for platforms and infrastructure layers – and not just individual products. If Circio gets an upfront deal or stronger BP validation, which I believe is entirely possible within the year, I'm not sure that an early acquisition is necessarily the most interesting outcome… And several major shareholders agree here! Because if our technology / platform actually gets validated more broadly, then it's hard to imagine anything other than the market's understanding of the case changing significantly! Yes - This is still risk biotech and some elements remain to be proven… ,but my assessment is that the risk/reward is very interesting here, precisely because the market still largely prices Circio essentially as a small Norwegian preclinical biotech company — while signals from the sector and BP point towards something potentially much larger! What happens if we actually get the validation they are working towards? I am a proponent of being able to think big! But even I can't quite imagine how big this could become!!?"
- ·5 t sittenhttps://strawpoll.com/7MZ0kLv7pgo Big Pharma who? Who do you think is testing circVec in CNS behind the scenes? (Feasibility study since November 2025) Vote who you BELIEVE, and not who you hope. As most know, it's a top 5 largest Big Pharma. I have added more than 5, as it's hard to assess who is actually bigger than whom. 💰·24 min sittenNovo. They have shut down their production on Funen. Brilliant if they could use the new factory for Circio 😁😁
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 953 | - | - | ||
| 7 618 | - | - | ||
| 784 | - | - | ||
| 357 | - | - | ||
| 33 323 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
39 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·7 min sittenTHEY ARE NOT SELLING A DRUG. THEY ARE SELLING THE KEY. 🧬🔑 There is a fundamental difference. A pharmaceutical company develops one treatment for one disease. One approval. One market. Circio does something else. They develop the technology that makes others' treatments better. AAV gene therapy has a dosing problem. circVec solves it. mRNA-based CAR-T lasts a few days. circVec lasts months. Liver expression is a toxicity problem. circVec reduces it. It is not one treatment. It is one key. And keys can be licensed to everyone who needs to unlock the same problem. Heart. Eye. CNS. CAR-T. Autoimmune diseases. Cancer. Vaccines. Each field is a new market. Each partner pays for access. It is not a product case. It is an infrastructure case. And infrastructure is not priced as one program. It is priced as control over an entire field. We know what we own. ♟️🧱🍷
- ·16 min sittenERIK SPEAKS THURSDAY 28. MAY. AT 10:00. 🧬🎤 This coming Thursday at 10:00, Erik Wiklund will hold a live webcast. He will summarize what actually happened in Boston at ASGCT. No dry press release. No interpretation of stock exchange announcements. Erik himself. Live. In Norwegian. You can submit questions in advance directly to erik.wiklund@circio.com. It is not often that a CEO in biotech sits down and explains the data face-to-face directly to the shareholders. Seize the opportunity. Submit questions about the in vivo program and the way forward. We know what we own. ♟️🧱🍷·9 min sittenBennyz, you know you think long-term, but what do you think about the next weeks with warrants? Do you think the stock will rise a bit so that people will buy their warrants?
- ·28 min sittenCircio, as is known, entered into an evaluation agreement in April with Acuitas Therapeutics to develop a new type of in vivo CAR-T cell therapy. News article at NRK today about what chief physician Fredrik Schjesvold says "is the best cancer treatment we have today". Too expensive - says the decision-making forum. News article within the professional field, for information for those who are interested. https://www.nrk.no/rogaland/beslutningsforum-seier-nei-for-andre-gong-til-_den-beste-kreftbehandlinga_-mot-beinmergskreft-1.17823907
- ·46 min sitten"Tekinvestor "Some thoughts and Ref. Lilly's Acquisition of Engage now - The most interesting thing is actually not BP's individual deals, but the pattern we can see emerging… Big Pharma no longer just buys finished medicines – they buy platforms that can potentially broadly improve genetic medicine - Delivery, expression, RNA technology, in vivo cell therapy etc. Engage Bio was thus now acquired by EL without published clinical data (as far as I can see) That says something about how much value BP now attributes to enablement technology and platform At the same time, Circio has shown very strong preclinical data received an oral presentation at ASGCT and gone from feasibility to in vivo with a BP partner. And more … Then the question is: What could circVec be worth if the technology actually proves to work broadly within AAV, LNP, and other in vivo solutions? To me, this looks more and more like a race for platforms and infrastructure layers – and not just individual products. If Circio gets an upfront deal or stronger BP validation, which I believe is entirely possible within the year, I'm not sure that an early acquisition is necessarily the most interesting outcome… And several major shareholders agree here! Because if our technology / platform actually gets validated more broadly, then it's hard to imagine anything other than the market's understanding of the case changing significantly! Yes - This is still risk biotech and some elements remain to be proven… ,but my assessment is that the risk/reward is very interesting here, precisely because the market still largely prices Circio essentially as a small Norwegian preclinical biotech company — while signals from the sector and BP point towards something potentially much larger! What happens if we actually get the validation they are working towards? I am a proponent of being able to think big! But even I can't quite imagine how big this could become!!?"
- ·5 t sittenhttps://strawpoll.com/7MZ0kLv7pgo Big Pharma who? Who do you think is testing circVec in CNS behind the scenes? (Feasibility study since November 2025) Vote who you BELIEVE, and not who you hope. As most know, it's a top 5 largest Big Pharma. I have added more than 5, as it's hard to assess who is actually bigger than whom. 💰·24 min sittenNovo. They have shut down their production on Funen. Brilliant if they could use the new factory for Circio 😁😁
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 953 | - | - | ||
| 7 618 | - | - | ||
| 784 | - | - | ||
| 357 | - | - | ||
| 33 323 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt